Pacific Biosciences of California, Inc.
PACBNASDAQHealthcareMedical Devices
As of Oct 16, 2026 close
- Market cap
- $608.88M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.07$3.44
- Volume (live)
- -
- Avg. volume (3M)
- 15.21M
Pacific Biosciences of California (PACB) Stock Price & Financial Analysis
Pacific Biosciences of California Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.70 - $1.96 |
|---|---|
| 52-Week High | $3.44 |
| 52-Week Low | $1.07 |
| Open | $1.96 |
| Volume (last close) | 10.43M |
| Average Volume (3M) | 15.21M |
| Revenue (TTM) | 159.27M |
|---|---|
| Net Income (TTM) | -131.39M |
| Free Cash Flow (TTM) | -171.16M |
| EPS (TTM) | −$0.43 |
| Profit Margin | -82.49% |
| Operating Margin | -102.09% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 608.88M |
|---|---|
| Shares Outstanding | 310.65M |
| Price to Sales (P/S) | 3.82 |
| Price to Book (P/B) | -18.33 |
| EV/EBITDA | -10.94 |
| 50-Day MA | $1.58 |
|---|---|
| 200-Day MA | $1.60 |
| 1-Year Change | +19.51% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Pacific Biosciences of California at a Glance
As of the Oct 16, 2026 close, Pacific Biosciences of California (PACB) has a market capitalization of $608.88M. The stock trades at 3.8× sales. Over the trailing twelve months it lost $131.39M on revenue of $159.27M and burned $171.16M of free cash flow. Revenue grew 2.0% year over year.
As of its latest reported balance sheet, it holds $61.00M in cash and securities against $645.70M of debt, a net debt position of $584.70M.
Pacific Biosciences of California does not currently pay a dividend.
The share price is up 19.5% over the past year. At $1.73 (the Oct 16, 2026 close) it sits within its 52-week range of $1.07 to $3.44, above its 200-day moving average of $1.59.
Based on 9 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $1.90, 9.8% above the Oct 16, 2026 close.
Frequently Asked Questions About Pacific Biosciences of California
What is the current stock price for PACB?
As of the Oct 16, 2026 close, PACB stock trades at $1.73. The 52-week range is $1.07–$3.44, with a day range of $1.70–$1.96.
What is the P/E ratio for PACB?
The P/E ratio (Price-to-Earnings) for PACB is shown in the Key Statistics section. This valuation metric helps compare Pacific Biosciences of California, Inc. to industry peers.
Does PACB pay dividends?
Pacific Biosciences of California does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for PACB?
Based on ratings from 9 professional analysts over the last 90 days, the consensus for PACB is Hold. The average 12-month price target is $1.90, a 9.8% upside from the Oct 16, 2026 close of $1.73.
What is the market cap of PACB?
As of the Oct 16, 2026 close, Pacific Biosciences of California's market capitalization is $537.4M, classifying it as a small-cap company. Pacific Biosciences of California operates in the Healthcare sector within the Medical Devices industry.